192 citations
,
March 1998 in “British Journal of Dermatology” This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly” March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2026 in “Updates in clinical dermatology” 4 citations
,
July 1987 in “Dermatologic Clinics” January 2022 in “Springer eBooks”
23 citations
,
January 2011 in “International Journal of Immunopathology and Pharmacology” In this small study, topical minoxidil 2% was associated with an increase in normal hair shaft production in patients with Monilethrix without any reported side effects.
November 1999 in “Reactions Weekly”
Minoxidil sulfate, delivered through iontophoresis, can be used to treat hair loss.
July 2026 in “Journal of Drug Delivery Science and Technology”
January 2018 in “Elsevier eBooks” This article reviews the mechanisms and uses of minoxidil for hypertension and androgenetic alopecia, without presenting new clinical findings.
March 2026 in “Mini-Reviews in Medicinal Chemistry” This review reports that pharmacogenomic variations in the SULT1A1 enzyme significantly influence the response to minoxidil treatment for alopecia, suggesting personalized therapeutic strategies could improve efficacy while emerging pharmaceutical technologies aim to optimize oral minoxidil's absorption and minimize side effects.
37 citations
,
May 2016 in “JAAD case reports” This abstract describes monilethrix, an autosomal dominant genodermatosis with symptoms like hair fragility and keratosis pilaris, and does not report new experimental results.
March 2021 in “Hair transplant forum international” This article provides an overview of minoxidil's application as a vasodilator for severe hypertension and its topical use for treating androgenetic alopecia, detailing its effective plasma threshold levels for hair growth induction without new findings.
January 2026 in “International Journal of Applied Pharmaceutics” This study developed a novel LC-ESI-MS/MS method to quantify Minoxidil in pharmaceutical forms, finding it precise, accurate, and robust. It withstands excipient and degradant interference, although Minoxidil degrades under some stress conditions but remains stable thermally.
November 2024 in “RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218” In this study, a literature review concluded that minoxidil is safe and effective for treating androgenetic alopecia, with few side effects, and highlighted the role of pharmacists in optimizing treatment by monitoring use and fostering adherence.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” December 2022 in “PubMed”
18 citations
,
July 1975 in “Clinical Pharmacology & Therapeutics” Oral minoxidil effectively controls blood pressure quickly and safely.
1 citations
,
September 2023 in “Journal of The American Academy of Dermatology” This abstract reviews the use of low dose oral minoxidil as a monotherapy for hair loss and reports no new clinical data.
July 2026 in “Mendeley Data”
September 2023 in “Journal of The American Academy of Dermatology” This review evaluates the clinical experience of using low-dose oral minoxidil for treating alopecia and highlights the ongoing concerns about its potential side effects without reporting new clinical results.
Minoxidil can cause hair growth as a side effect.
January 1987 in “Chronica Dermatologica”